Lucentis and Simbrinza drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lucentis (ranibizumab) and Simbrinza (brimonidine tartrate; brinzolamide). Common drug interactions include visual impairment among females and ocular hypertension among males.

The phase IV clinical study analyzes what interactions people have when they take Lucentis and Simbrinza. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Simbrinza?

Simbrinza has active ingredients of brimonidine tartrate; brinzolamide. It is often used in glaucoma. eHealthMe is studying from 4,543 Simbrinza users. Check the latest studies of Simbrinza.

On Jul, 11, 2026

17 people who take Lucentis and Simbrinza together, and have interactions are studied.

Lucentis and Simbrinza drug interactions.

What are the common drug interactions of Lucentis and Simbrinza, by gender? *:

female:

Visual impairment
Drug intolerance (drug sensitivity)
Headache (pain in head)
Intraocular pressure increased
Ocular hyperaemia (an abnormally large amount of blood in eye)
Blindness unilateral
Metamorphopsia (a type of distorted vision in which a grid of straight lines appears wavy and parts of the grid may appear blank)
Vision blurred
Eye irritation
Eye pain

male:

Ocular hypertension (intraocular pressure higher than normal)
Acne (skin problems that cause pimples)
Infection
Ocular hyperaemia (an abnormally large amount of blood in eye)
Pain
Rash
Reading disorder (problem in areas of the brain that help interpret language)
Visual impairment
Vitreous floaters (spots before the eyes)
Blood bilirubin increased

What are the common drug interactions of Lucentis and Simbrinza, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Discomfort
Dry eye (lack of adequate tears)
Eye pain
Macular oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken)
Punctate keratitis (inflammation of the cornea with tiny spots)
Vision blurred
Visual impairment
Iritis (painful inflammation of the iris of the eye)
Uveitis (inflammation of the uvea)

60+:

Headache (pain in head)
Intraocular pressure increased
Deafness
Fall
Gait disturbance
General physical health deterioration (weak health status)
Hypothalamo-pituitary disorder (loss of function in an endocrine gland due to failure of the pituitary gland to secrete hormones which stimulate that gland's function)
Nasopharyngitis (inflammation of the nasopharynx)
Negative thoughts
Blood bilirubin increased

What are the existing conditions these people have? *

Venous Occlusion (the blocking of venous return): 2 people, 11.76%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 2 people, 11.76%
Polymyalgia Rheumatica (pain in many muscles): 1 person, 5.88%
Pneumonia: 1 person, 5.88%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 1 person, 5.88%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 1 person, 5.88%
Cystoid Macular Oedema (fluid accumulation after cataract surgery): 1 person, 5.88%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 1 person, 5.88%
Cellulitis (infection under the skin): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and Simbrinza?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously